Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt

MT Newswires Live2024-12-18

Esperion Therapeutics (ESPR) said Wednesday it has completed a series of financing agreements to repay a part of its current $265 million convertible debt facility.

The company said it obtained a $150 million senior term loan led by funds managed by Athyrium Capital Management and joined by funds managed by HealthCare Royalty. Esperion added that it also issued new $100 million convertible notes to accredited investors.

The new notes will mature on June 15, 2030, and will bear a semiannual interest payment, the company said.

Esperion said it intends to use the loan proceeds and roughly $60 million of the proceeds from the new notes to repay $210 million of the current convertible debt, while the remaining $40 million of the proceeds would be allocated as operating cash.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492627185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492627185","market":"fut","top_or_hot":-1,"title":"Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt","media":"MT Newswires Live","content":"<html><body><p> Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ESPR) said Wednesday it has completed a series of financing agreements to repay a part of its current $265 million convertible debt facility.</p><p>The company said it obtained a $150 million senior term loan led by funds managed by Athyrium Capital Management and joined by funds managed by HealthCare Royalty. Esperion added that it also issued new $100 million convertible notes to accredited investors.</p><p>The new notes will mature on June 15, 2030, and will bear a semiannual interest payment, the company said.</p><p>Esperion said it intends to use the loan proceeds and roughly $60 million of the proceeds from the new notes to repay $210 million of the current convertible debt, while the remaining $40 million of the proceeds would be allocated as operating cash.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 21:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Esperion Therapeutics (ESPR) said Wednesday it has completed a series of financing agreements to repay a part of its current $265 million convertible debt facility.The company said it obtained a $150 ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492627185","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492627185","pubTimestamp":1734528876,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Esperion Therapeutics  said Wednesday it has completed a series of financing agreements to repay a part of its current $265 million convertible debt facility.The company said it obtained a $150 million senior term loan led by funds managed by Athyrium Capital Management and joined by funds managed by HealthCare Royalty. Esperion added that it also issued new $100 million convertible notes to accredited investors.The new notes will mature on June 15, 2030, and will bear a semiannual interest payment, the company said.Esperion said it intends to use the loan proceeds and roughly $60 million of the proceeds from the new notes to repay $210 million of the current convertible debt, while the remaining $40 million of the proceeds would be allocated as operating cash.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Esperion Therapeutics完成融资交易以部分偿还可转换债务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1},"content_text":"Esperion Therapeutics (ESPR) said Wednesday it has completed a series of financing agreements to repay a part of its current $265 million convertible debt facility.The company said it obtained a $150 million senior term loan led by funds managed by Athyrium Capital Management and joined by funds managed by HealthCare Royalty. Esperion added that it also issued new $100 million convertible notes to accredited investors.The new notes will mature on June 15, 2030, and will bear a semiannual interest payment, the company said.Esperion said it intends to use the loan proceeds and roughly $60 million of the proceeds from the new notes to repay $210 million of the current convertible debt, while the remaining $40 million of the proceeds would be allocated as operating cash.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492627185"}